I
N 1970, THE ANTHRAX VACCINE WAS licensed by the US Food and Drug Administration for human use. 1 Independent civilian panels have repeatedly affirmed the safety and efficacy of the anthrax vaccine. [1] [2] [3] [4] [5] Until 1990, the primary recipients of this vaccine were individuals occupationally exposed to anthrax (textile mill workers, selected veterinarians, certain laboratory workers). With the advent of the Persian Gulf War, the US Department of Defense determined there was a credible threat of anthrax exposure to its troops from biological weapons and a large-scale vaccination program with anthrax vaccine was started.
Due to the persistent threat of biological weapons use, the US Department of Defense directed in 1998 that all military services begin an anthrax vaccination program. [6] [7] [8] [9] The US military has given more than 2 million anthrax vaccinations to more than 500000 individuals since beginning the vaccination program. Military personnel at Fort Stewart, Ga, and Hunter Army Airfield, Ga, began a program of anthrax vaccinations in the fall of 1998. Medical exemptions to vaccination were granted as clinically appropriate, the most common being deferral of vaccination during pregnancy. The program continued until March 2000, when it was curtailed because of a shortage of vaccine. After March 2000, new vaccine starts were limited to persons assigned to "high-threat" areas.
Anthrax vaccine adsorbed, distributed by BioPort Corp (Lansing, Mich), consists of aluminum hydroxideadsorbed supernatant material, principally protective antigen, from an avirulent, nonencapsulated strain of Bacillus anthracis. 1, 10 There is no live material in this vaccine. The vaccine series consists of 6 doses over 18 months, followed by an annual booster. Injectionsite reactions (principally due to the aluminum hydroxide) have been well described. 1, 4, [10] [11] [12] [13] Limited studies of longterm effects found no evidence of adverse consequences. 13, 14 Although no biologically plausible mechanism for a reproductive effect has ever been proposed, this vaccine is administered to large numbers of women in their early reproductive years. Questions relating to reproductive effects are the most common concerns among callers to the US Department of Defense's anthrax toll-free information line (LTC J. D. 
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METHODS
Population
The study population was US Army women aged 17 to 44 years assigned to Fort Stewart, Ga, or Hunter Army Airfield, Ga, at any time during January 1999 through March 2000. Demographic information, period of assignment, and anthrax immunization dates were obtained from local administrative and clinical databases. All outcome information (pregnancy, birth, and adverse birth outcome) was obtained from the Fort Stewart Hospital's computerized database. The study design was reviewed and approved by the institutional review board at Dwight David Eisenhower Army Medical Center, Augusta, Ga.
Outcome Measures
The primary outcome measure was pregnancy. Additional outcomes were birth following pregnancy and adverse birth outcomes. A woman was considered pregnant if a qualitative serum or urine ␤-human chorionic gonadotropin (hCG) test result was positive or a quantitative serum test was more than 5 IU/mL, or if she was hospitalized and discharged with an International Classification of Diseases, 9th Revision (ICD-9) diagnosis that included live birth and was assigned to Fort Stewart for at least 270 days prior to the birth. Live births included all ICD-9 diagnosis codes of 640 to 679, but excluded those codes whose fifth digit was a 3 or 4 (admitted either for a prepartum complication without delivery or for postpartum complication without delivery, respectively). The ICD-9 codes were used to define low birth weights (764-765) and congenital structural abnormalities (740-759). Low birth weight was defined as infants weighing less than 2500 g at birth. 15, 16 were examined as possible confounding factors. Age and marital status were assessed at the beginning of the study period. Race was subdivided into categories of black, white, and all other, which included Hispanic, American Indian, Pacific Islander, and Asian.
Statistical Methods
A general log-linear model, using the Poisson distribution, was used to estimate rates and rate ratios for predictor variables. Model building and goodnessof-fit testing were performed using standard methods. 17 Unconditional logistic regression was used to estimate odds ratios (ORs) for birth outcome following pregnancy. Univariate comparisons were made between pregnancy occurrence and major demographic variables. Statistical analyses were performed using SPSS software, version 10.0 (SPSS Inc, Chicago, Ill). For 90% power to detect a 25% decline in pregnancy rates, assuming the fraction exposed to anthrax vaccine was 75%, the pregnancy rate was 160 pregnancies per 1000 women per year and the type 1 error held at 5% (2-sided), a total sample size of 4000 women was required. Power estimates were based on known prestudy anthrax vaccine exposure rate (47%), expected rate of rise, and previous estimates of pregnancy rates in military women (A.R.W., unpublished data, 2001). All confidence intervals (CIs) were 2-sided.
RESULTS
During the 15-month study period, 4098 women were assigned to Fort Stewart or Hunter Army Airfield. Six women were excluded because of incomplete data, leaving 4092 women eligible for data analysis; 3136 women received at least 1 dose of anthrax vaccine. There were no important demographic differences between those vaccinated and not vaccinated, except for a slight difference in racial distribution (TABLE 1). The most common reason for not being vaccinated was departure from Fort Stewart before the vaccine could be given. Persons already at Fort Stewart or Hunter Army Airfield were vaccinated as rapidly as time, training, vaccine supply, and medical resources allowed. Vaccine was 
12).
Women who received the anthrax vaccination were 1.2 times as likely to give birth as unvaccinated women (95% CI, 0.8-1.8; P =.52). The OR after adjustment for marital status, race, and age was unchanged (OR, 1.2; 95% CI, 0.7-1.8; P=.53). Eighty-five women left Fort Stewart within 260 days of their positive pregnancy test but 54 women remained eligible for medical care in the military system. Six had laboratory evidence of fetal loss prior to departing Fort Stewart. Of the 25 pregnancies lost to follow-up, 12 of the women received the anthrax vaccine and 13 did not. These women were younger, significantly less likely to have been vaccinated, and more likely to be single and white (TABLE 3) . If the 488 women with at least 260 days of follow-up are considered (TABLE 4), the OR for birth and anthrax vaccination was 0.9 (95% CI, 0.5-1.4; P=.55). The OR after adjustment for marital status, race, and age was unchanged (OR, 0.9; 95% CI, 0.5-1.4).
Complete ICD-9 coding data for 327 births were available for birth outcome analysis. Eleven (3.3%) of the births were of low birth weight (Ͻ2500 g). The OR for anthrax vaccination and low birth weight, after adjusting for age, was 1.3 (95% CI, 0.2-6.4; P=.72). There were 15 structural abnormalities of cosmetic and/or medical significance (ICD-9 codes 740-759). No unusual patterns or clusters were noted. The only abnormality with multiple occurrences was polydactyly of the fingers (3 cases: 2 in the anthrax immunized group and 1 in the nonimmunized group). The OR for anthrax vaccination and structural abnormality, after adjusting for age, was 0.7 (95% CI, 0.2-2.3; P = .71). The overall OR for anthrax vaccination and any adverse birth outcome, after adjusting for age, was 0.9 (95% CI, 0.4-2.4; P=.88).
COMMENT
When the US Department of Defense began immunizing military personnel with the anthrax vaccine, its use was questioned by many receiving the vaccine, for only those exposed to an anthrax biological weapon would benefit. Because most would not be exposed, the attention of many service members turned to potential risks. This is the first study to our knowledge to examine the effects on reproduction among a large group of women given the anthrax vaccine. In a previous study on pregnancy in Army women (A.R.W., unpublished data, 2001), we found a pregnancy rate of 161 per 1000 person-years in 5500 women followed up for more than 66000 person-months. When this cohort was standardized for age and race to the 1995 US population, the pregnancy rate ratio was 1.05 (95% CI, 0.96-1.04). Furthermore, the pregnancy rate at Fort Stewart and Hunter Army Airfield during the 32 months prior to the study period was not statistically significantly different from the rate during the study (rate ratio = 1.0; 95% CI, 0.9-1.1; P =.90). These results do not support the hypothesis of a decrease in pregnancy rates nor an increase in fetal loss rates or adverse fetal outcome among those receiving anthrax vaccination prior to pregnancy. Although the number of adverse outcomes was small, the percentage of low-birth-weight infants was about half the expected 7.5% of low-birth-weight infants seen nationwide. [18] [19] [20] [21] This may be due to the young age of women in our cohort. The structural abnormality rate was comparable with national rates.
22,23 This is not surprising, given the lack of a biologically plausible mechanism for any reproductive effect.
In addition, there is no evidence of infertility, miscarriages, or other reproductive problems with the use of any inactivated vaccine. 24, 25 For example, tetanus, meningococcal, hepatitis B, poliovirus, and influenza vaccines are specifically recommended for susceptible women during their pregnancy. 26 This study has several strengths. First, there is the nonbiased nature of the exposure to vaccine. This military post had a blanket policy for immunization. Hence, potentially important independent risk factors, such as intent to become pregnant, use of contraceptives, marital status, age, race, and smoking status, were not related to vaccine exposure and therefore could not confound the results. There are no known medical conditions related to fertility and pregnancy that would have exempted a woman from receiving the anthrax vaccine. Second, another strength is the objectivity and completeness of the outcomes. Personnel on active military service have little opportunity to receive health care outside the military system; health care is free and testing to document pregnancy is required. Therefore, we are confident that we captured the vast majority of all pregnancies. All the medical testing at Fort Stewart is done at the installation's hospital and the results are maintained in a single computerized database. Finally, the study size provides confidence that the hypothesis regarding rate of pregnancy was not inappropriately rejected due to lack of study power.
There are several potential limitations to this study. First, there is our reliance on the accuracy of ICD-9 coding. This is unlikely to introduce a significant bias as any miscodings would be expected to be equally distributed over both the vaccinated and unvaccinated groups. Second, we were unable to adjust for other potentially important confounders such as intent to become pregnant and smoking status. However, these were not related to the exposure to anthrax vaccine and should not confound the results. Third, it was not possible to test for dose response. The vaccine schedule calls for the first 3 immunizations to be given in the first month, then the next 3 to be given at 6-month intervals. This led to most participants receiving either 3 or 4 immunizations with insufficient numbers receiving less or more vaccine to permit a meaningful analysis of dose response. However, given the lack of overall effect, it is unlikely that a significant dose response effect is present. Fourth, there was no way to evaluate the effect of the vaccine given during pregnancy; only prepregnancy vaccine exposure was evaluated. Finally, the study does not have adequate statistical power to rule out a small effect of vaccination on adverse birth outcome, given the low incidence of adverse outcomes. A post hoc power analysis showed the study only had a 12% power to detect a 20% increase in adverse birth outcomes, based on potential effects on likelihood of pregnancy.
